Navigation Links
Senesco Announces H1N1 Influenza Survival Test Results in Mice
Date:5/26/2009

NEW BRUNSWICK, N.J., May 26 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported results of H1N1 mouse influenza survival studies that were conducted in Dr. William Scheld's lab at the University of Virginia School of Medicine. Mice treated with an siRNA against Senesco's Factor 5A gene had a 52% survival rate as opposed to a 14% survival rate for mice that received no treatment or a control siRNA.

A total of 73 mice were infected with a lethal dose of nasally administered H1N1 mouse influenza. The treated mice (n=31 mice) were administered Senesco's siRNA against Factor 5A approximately 24 hours after infection and then every other day for 11 days. Treated mice reversed the weight loss typically seen in infected mice at around day 8 of the study, which coincides with the reduced mortality. The treated mice had other reduced indicators of disease severity as measured by blood glucose and liver enzymes.

Dr. Scheld, the Bayer-Gerald L. Mandell Professor of Internal Medicine at the University of Virginia School of Medicine and past president of the Infectious Diseases Society of America, commented, "These prototype studies have demonstrated that Factor 5A is a promising candidate for future study in several infectious diseases, including a model of lethal influenza."

Bruce Galton, Senesco's President and CEO, added, "We believe these data from Dr. Scheld further underscore Factor 5A's ability to mitigate apoptosis caused by inflammation, in this case from the H1N1 flu model. As we have previously stated, one of the attributes of Senesco's Factor 5A technology is its broad applicability. While we are currently working on our primary goal of filing an investigational new drug application with the FDA for the treatment of multiple myeloma, it is important that our other inflammation programs also progress."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate a financing; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:
    Senesco Technologies, Inc.
    Bruce Galton
    Chief Executive Officer
    bgalton@senesco.com
    (732) 296-8400

    Investor Relations Contact:       Media Relations:
    FD                                FD
    Brian Ritchie                     Irma Gomez-Dib
    brian.ritchie@fd.com              irma.gomez-dib@fd.com
    212-850-5600                      212-850-5600


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Senesco Chooses VGXI to Produce Factor 5A Plasmid
2. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
3. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
4. Senesco Technologies Initiates Preclinical Studies for Cancer Target
5. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
6. Telik Announces Presentation at ASCO Annual Meeting
7. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
10. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
11. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):